- Home
- PGRE vs PCRX Comparison
PGRE vs PCRX Comparison
Compare PGRE & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- PCRX
- Stock Information
- Founded
- PGRE 1978
- PCRX 2006
- Country
- PGRE United States
- PCRX United States
- Employees
- PGRE N/A
- PCRX N/A
- Industry
- PGRE Real Estate Investment Trusts
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PGRE Real Estate
- PCRX Health Care
- Exchange
- PGRE Nasdaq
- PCRX Nasdaq
- Market Cap
- PGRE 1.3B
- PCRX 1.2B
- IPO Year
- PGRE 2014
- PCRX 2011
- Fundamental
- Price
- PGRE $6.81
- PCRX $22.73
- Analyst Decision
- PGRE Hold
- PCRX Buy
- Analyst Count
- PGRE 4
- PCRX 8
- Target Price
- PGRE $5.63
- PCRX $28.38
- AVG Volume (30 Days)
- PGRE 3.5M
- PCRX 492.0K
- Earning Date
- PGRE 07-30-2025
- PCRX 07-29-2025
- Dividend Yield
- PGRE N/A
- PCRX N/A
- EPS Growth
- PGRE N/A
- PCRX N/A
- EPS
- PGRE N/A
- PCRX N/A
- Revenue
- PGRE $711,729,000.00
- PCRX $702,772,000.00
- Revenue This Year
- PGRE $1.41
- PCRX $7.92
- Revenue Next Year
- PGRE N/A
- PCRX $11.02
- P/E Ratio
- PGRE N/A
- PCRX N/A
- Revenue Growth
- PGRE 49.28
- PCRX 3.08
- 52 Week Low
- PGRE $3.75
- PCRX $11.16
- 52 Week High
- PGRE $6.89
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- PGRE 74.06
- PCRX 36.58
- Support Level
- PGRE $5.96
- PCRX $22.23
- Resistance Level
- PGRE $6.72
- PCRX $23.91
- Average True Range (ATR)
- PGRE 0.18
- PCRX 0.82
- MACD
- PGRE 0.04
- PCRX -0.01
- Stochastic Oscillator
- PGRE 98.39
- PCRX 22.03
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.